Glucagon intranasal (Eli Lilly/Locemia Solutions)

鼻用高血糖素

Report date: 2024/07/02 10:52:49

Base Information

Drug NameGlucagon intranasal (Eli Lilly/Locemia Solutions)
Drug Alias Name高血糖素鼻用粉雾剂Nasal Glucagon - Locemia SolutionsIN glucagon - Locemia SolutionsGlucagon - Locemia SolutionsDry-mist intranasal glucagon - Locemia Solutions +[8] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonists
TargetsGlucagon receptor
Therapy Area/IndicationsHypoglycemiaDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1 +[4] 
Global Approved IndicationsHypoglycemia
Approved Indications in ChinaHypoglycemia
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/24
Country/TerritoryCanadaUnited StatesGermany +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAmg MedicalLocemia Solutions
China Registration ClassN/A

Develop Information

Active CompaniesAmphastar France Pharmaceuticals SasAmphastar Pharmaceuticals Inc
Inactive CompaniesEli Lilly And CompanyUniversity Health Network (Uhn)
Active IndicationsHypoglycemia
Inactive IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1Diabetes Mellitus

Other Information

ATC CodeH04AA01
Related LinksN/A